特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

慢性手湿疹(CHE)- 疫学予測 2030年

Chronic Hand Eczema (CHE) - Epidemiology Forecast - 2030

発行 DelveInsight Business Research LLP 商品コード 928276
出版日 ページ情報 英文 111 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
慢性手湿疹(CHE)- 疫学予測 2030年 Chronic Hand Eczema (CHE) - Epidemiology Forecast - 2030
出版日: 2020年03月01日 ページ情報: 英文 111 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における慢性手湿疹(CHE)の2017年の有病数は422万9,215人と推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の慢性手湿疹(CHE)市場を調査し、疾病の概要、重症度・病型・年齢・性別の疫学的予測、主要7カ国の動向などをまとめています。

目次

第1章 主な洞察

第2章 エグゼクティブサマリー

第3章 慢性手湿疹:患者の概要

  • 患者分布(実数値)
  • 患者分布(予測値)

第4章 疫学と市場調査手法

第5章 組織

第6章 慢性手湿疹(CHE):疾患の背景と概要

  • イントロダクション
  • 分類
  • 病因
  • 症状
  • 危険因子
  • 原因
  • 重症度と治療反応の定義
  • 診断
  • 診断アルゴリズム

第7章 疫学と患者人口

  • 主な調査結果

第8章 主要7カ国の慢性手湿疹(CHE)の総有病数

第9章 米国の疫学

  • 仮定と根拠
    • 総有病数
    • 有病数:性別
    • 診断数
    • 症例数:重症度別
    • 症例数:病型別
    • 症例数:年齢別

第10章 欧州5カ国の疫学

  • ドイツ
    • 総有病数
    • 有病数:性別
    • 診断数
    • 症例数:重症度別
    • 症例数:病型別
    • 症例数:年齢別
  • フランス
  • イタリア
  • スペイン
  • 英国

第11章 日本の疫学

  • 仮定と根拠
    • 総有病数
    • 有病数:性別
    • 診断数
    • 症例数:重症度別
    • 症例数:病型別
    • 症例数:年齢別

第12章 キーオピニオンリーダーの見解

第13章 付録

第14章 調査手法

第15章 DelveInsightのサービス内容

第16章 免責事項

第17章 DelveInsightについて

図表

List of Tables

  • Table 1 Classification of Hand Eczema
  • Table 2 Definition of subtypes of hand eczema
  • Table 3 Etiological classification of Hand Eczema
  • Table 4 Morphological classification of Hand Eczema
  • Table 5 Characteristics of the various sub diagnostic groups
  • Table 6 Subgroups of hand eczema and definitions
  • Table 7 Risk factors for the development of HE
  • Table 8 Physician's global assessment for chronic hand eczema
  • Table 9 Modified total lesion-symptom score
  • Table 10 Scoring of the patch test according to ICDRG recommendations
  • Table 11 Diagnostic Evaluation of Hand Eczema
  • Table 12 Signs and symptoms of superficially similar lesions of the hand eczema
  • Table 13 Recommendations for the Classification and diagnosis of Hand Eczema
  • Table 14 Total Prevalent Cases of Chronic Hand Eczema in the 7MM (2017-2030)
  • Table 15 Total Prevalent Cases of Chronic Hand Eczema in the US (2017-2030)
  • Table 16 Gender-Specific Cases of CHE in the US (2017-2030)
  • Table 17 Diagnosed Cases of Chronic Hand Eczema in the US (2017-2030)
  • Table 18 Severity Specific Cases of CHE in the US (2017-2030)
  • Table 19 Subgroup Specific Cases of CHE in the US (2017-2030)
  • Table 20 Age-Specific Cases of CHE in the US (2017-2030)
  • Table 21 Total Prevalent Cases of Chronic Hand Eczema in Germany (2017-2030)
  • Table 22 Gender-Specific Cases of CHE in Germany (2017-2030)
  • Table 23 Diagnosed Cases of Chronic Hand Eczema in Germany (2017-2030)
  • Table 24 Severity Specific Cases of CHE in Germany (2017-2030)
  • Table 25 Subgroup Specific Cases of CHE in Germany (2017-2030)
  • Table 26 Age-Specific Cases of CHE in Germany (2017-2030)
  • Table 27 Total Prevalent Cases of Chronic Hand Eczema in France (2017-2030)
  • Table 28 Gender-Specific Cases of CHE in France (2017-2030)
  • Table 29 Diagnosed Cases of Chronic Hand Eczema in France (2017-2030)
  • Table 30 Severity Specific Cases of CHE in France (2017-2030)
  • Table 31 Subgroup Specific Cases of CHE in France (2017-2030)
  • Table 32 Age-Specific Cases of CHE in France (2017-2030)
  • Table 33 Total Prevalent Cases of Chronic Hand Eczema in Italy (2017-2030)
  • Table 34 Gender-Specific Cases of CHE in Italy (2017-2030)
  • Table 35 Diagnosed Cases of Chronic Hand Eczema in Italy (2017-2030)
  • Table 36 Severity Specific Cases of CHE in Italy (2017-2030)
  • Table 37 Subgroup Specific Cases of CHE in Italy (2017-2030)
  • Table 38 Age-Specific Cases of CHE in Italy (2017-2030)
  • Table 39 Total Prevalent Cases of Chronic Hand Eczema in Spain (2017-2030)
  • Table 40 Gender-Specific Cases of CHE in Spain (2017-2030)
  • Table 41 Diagnosed Cases of Chronic Hand Eczema in Spain (2017-2030)
  • Table 42 Severity Specific Cases of CHE in Spain (2017-2030)
  • Table 43 Subgroup Specific Cases of CHE in Spain (2017-2030)
  • Table 44 Age-Specific Cases of CHE in Spain (2017-2030)
  • Table 45 Total Prevalent Cases of Chronic Hand Eczema in the UK (2017-2030)
  • Table 46 Gender-Specific Cases of CHE in the UK (2017-2030)
  • Table 47 Diagnosed Cases of Chronic Hand Eczema in the UK (2017-2030)
  • Table 48 Severity Specific Cases of CHE in the UK (2017-2030)
  • Table 49 Subgroup Specific Cases of CHE in the UK (2017-2030)
  • Table 50 Age-Specific Cases of CHE in the UK (2017-2030)
  • Table 51 Total Prevalent Cases of Chronic Hand Eczema in Japan (2017-2030)
  • Table 52 Gender-Specific Cases of CHE in Japan (2017-2030)
  • Table 53 Diagnosed Cases of Chronic Hand Eczema in Japan (2017-2030)
  • Table 54 Severity Specific Cases of CHE in Japan (2017-2030)
  • Table 55 Subgroup Specific Cases of CHE in Japan (2017-2030)
  • Table 56 Age-Specific Cases of CHE in Japan (2017-2030)

List of Figures

  • Figure 1 Epidemiology and Market Methodology
  • Figure 2 Establish the diagnosis of acute hand dermatitis and chronic hand dermatitis (CHD)
  • Figure 3 Skin immune system
  • Figure 4 Photographic severity guide used in the physician's global assessment scoring
  • Figure 5 Flow chart for diagnosis of HE
  • Figure 6 Diagnostic chronic hand eczema (CHE) algorithm
  • Figure 7 Total Prevalent Cases of Chronic Hand Eczema in the 7MM (2017-2030)
  • Figure 8 Total Prevalent cases of Chronic Hand Eczema in the US (2017-2030)
  • Figure 9 Gender-Specific cases of CHE in the US (2017-2030)
  • Figure 10 Diagnosed Cases of Chronic Hand Eczema in the US (2017-2030)
  • Figure 11 Severity Specific Cases of CHE in the US (2017-2030)
  • Figure 12 Subgroup Specific Cases of CHE in the US (2017-2030)
  • Figure 13 Age-Specific Cases of CHE in the US (2017-2030)
  • Figure 14 Total Prevalent cases of Chronic Hand Eczema in Germany (2017-2030)
  • Figure 15 Gender-Specific cases of CHE in Germany (2017-2030)
  • Figure 16 Diagnosed Cases of Chronic Hand Eczema in Germany (2017-2030)
  • Figure 17 Severity Specific Cases of CHE in Germany (2017-2030)
  • Figure 18 Subgroup Specific Cases of CHE in Germany (2017-2030)
  • Figure 19 Age-Specific Cases of CHE in Germany (2017-2030)
  • Figure 20 Total Prevalent cases of Chronic Hand Eczema in France (2017-2030)
  • Figure 21 Gender-Specific cases of CHE in France (2017-2030)
  • Figure 22 Diagnosed Cases of Chronic Hand Eczema in France (2017-2030)
  • Figure 23 Severity Specific Cases of CHE in France (2017-2030)
  • Figure 24 Subgroup Specific Cases of CHE in the US (2017-2030)
  • Figure 25 Age-Specific Cases of CHE in France (2017-2030)
  • Figure 26 Total Prevalent cases of Chronic Hand Eczema in Italy (2017-2030)
  • Figure 27 Gender-Specific cases of CHE in Italy (2017-2030)
  • Figure 28 Diagnosed Cases of Chronic Hand Eczema in Italy(2017-2030)
  • Figure 29 Severity Specific Cases of CHE in Italy (2017-2030)
  • Figure 30 Subgroup Specific Cases of CHE in Italy (2017-2030)
  • Figure 31 Age-Specific Cases of CHE in Italy (2017-2030)
  • Figure 32 Total Prevalent cases of Chronic Hand Eczema in Spain (2017-2030)
  • Figure 33 Gender-Specific cases of CHE in Spain (2017-2030)
  • Figure 34 Diagnosed Cases of Chronic Hand Eczema in Spain (2017-2030)
  • Figure 35 Severity Specific Cases of CHE in Spain (2017-2030)
  • Figure 36 Subgroup Specific Cases of CHE in Spain (2017-2030)
  • Figure 37 Age-Specific Cases of CHE in Spain (2017-2030)
  • Figure 38 Total Prevalent cases of Chronic Hand Eczema in the UK (2017-2030)
  • Figure 39 Gender-Specific cases of CHE in the UK (2017-2030)
  • Figure 40 Diagnosed Cases of Chronic Hand Eczema in the UK (2017-2030)
  • Figure 41 Severity Specific Cases of CHE in the UK (2017-2030)
  • Figure 42 Subgroup Specific Cases of CHE in the UK (2017-2030)
  • Figure 43 Age-Specific Cases of CHE in the UK (2017-2030)
  • Figure 44 Total Prevalent cases of Chronic Hand Eczema in Japan (2017-2030)
  • Figure 45 Gender-Specific cases of CHE in Japan (2017-2030)
  • Figure 46 Diagnosed Cases of Chronic Hand Eczema in Japan (2017-2030)
  • Figure 47 Severity Specific Cases of CHE in Japan (2017-2030)
  • Figure 48 Subgroup Specific Cases of CHE in Japan (2017-2030)
  • Figure 49 Age-Specific Cases of CHE in Japan (2017-2030)
目次
Product Code: DIEI0878

DelveInsight's 'Chronic Hand Eczema (CHE)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the CHE, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Chronic Hand Eczema (CHE) Disease Understanding

Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belongs to the most common skin disorder exclusively localized to the hands. It is a highly prevalent, multi-etiological disease with a wide spectrum of severity and chronicity. In a substantial number of patients, HE can develop into a chronic condition, which remains active even after avoidance potentially damaging allergens and/or irritants.

Chronic Hand Eczema (CHE) has been defined as a long-lasting, relapsing course of Hand Eczema that is

  • Disease duration of at least 3 months or more than 3 flares within the last 12 months,
  • Unresponsive to standard treatment with emollients and topical corticosteroids for more than 3 months,
  • The recurrence of symptoms two or more times within a year despite adequate treatment.
  • No dominating active severe skin diseases or acute skin infections

CHE as an anatomoclinic syndrome with multifactorial origins that is not restricted to allergic or orthoergic origin. Clinical features include localization of eczema to the hands and fingers, including dryness, erythema, edema, hyperkeratosis, scaling, lichenification, vesiculation/blistering, fissures, pruritus, and pain. It is typically a dynamic condition extending over the years, and its morphology may change with time, both clinically and histologically. Erythema, edema, and vesicles are characteristic of acute eczema, whereas infiltration, hyperkeratosis, and fissures are seen in chronic eczema. It has significant morbidity and lost earnings and has severe negative impacts on the social and psychosocial aspects of patients' lives.

Chronic Hand Eczema (CHE) Epidemiology

The CHE epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total diagnosed prevalent cases of Chronic Hand Eczema (CHE) patients 7MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted CHE symptoms epidemiology segmented as the Total prevalence of CHE, Gender-Specific cases of CHE, Diagnosed cases of CHE, Age-Specific cases of CHE, Severity Specific Cases of CHE and Subgroup Specific Cases of CHE. The report includes the prevalent scenario of CHE symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

The prevalence of Chronic Hand Eczema (CHE) in the 7MM is expected to increase during the study period of 2017-2030.

Country Wise- Chronic Hand Eczema (CHE) Epidemiology

The epidemiology segment also provides the Chronic Hand Eczema (CHE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

According to DelveInsight, The total prevalent population of CHE Associated in 7MM countries ranges from 4,229,215 in 2017.

  • As per the estimates, United States has the highest prevalent population of CHE.
  • Among the EU5 countries, Germany had the highest prevalent population of CHE, followed by France and the UK. On the other hand, Spain had the lowest prevalent population in 2017.
  • On the other hand, Japan had 632,395 prevalent cases of Chronic Hand Eczema in 2017.

Scope of the Report

  • The Chronic Hand Eczema (CHE) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Chronic Hand Eczema (CHE) Epidemiology Report and Model provide an overview of the risk factors and global trends of Chronic Hand Eczema (CHE) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Chronic Hand Eczema (CHE) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of CHE
  • The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Prevalent Cases of Chronic Hand Eczema (CHE) in 7MM.
  • The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Gender - specific Prevalent Cases of Chronic Hand Eczema (CHE) in 7MM.
  • The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Age-specific Prevalent Cases of Chronic Hand Eczema (CHE) in 7MM.
  • The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Sub group-specific Cases of Chronic Hand Eczema (CHE) in 7MM
  • The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Diagnosed Cases of Chronic Hand Eczema (CHE) in 7MM
  • The report provides the segmentation of the Chronic Hand Eczema (CHE) epidemiology by Severity Specific Cases of Chronic Hand Eczema (CHE) in 7MM

Report Highlights

  • 11-Year Forecast of Chronic Hand Eczema (CHE) epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Chronic Hand Eczema (CHE)
  • Prevalent Cases according to segmentation: Age-specific Prevalence of CHE
  • Prevalent Cases according to segmentation: Gender-specific Prevalence of CHE
  • Prevalent Cases according to segmentation: Diagnosed cases of CHE
  • Prevalent Cases according to segmentation: Severity Specific cases of CHE
  • Prevalent Cases according to segmentation: Subgroup Specific Cases of CHE

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CHE?
  • What are the key findings pertaining to the Chronic Hand Eczema (CHE) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Chronic Hand Eczema (CHE) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the CHE?
  • What are the currently available treatments of CHE?

Reasons to buy

The Chronic Hand Eczema (CHE) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Chronic Hand Eczema (CHE) market
  • Quantify patient populations in the global Chronic Hand Eczema (CHE) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chronic Hand Eczema (CHE) therapeutics in each of the markets covered
  • Understand the magnitude of Chronic Hand Eczema (CHE) population by its Prevalence cases
  • Understand the magnitude of Chronic Hand Eczema (CHE) population by its Gender-specific cases
  • Understand the magnitude of Chronic Hand Eczema (CHE) population by its Age-specific cases
  • Understand the magnitude of Chronic Hand Eczema (CHE) population by its Diagnosed- specific cases
  • Understand the magnitude of Chronic Hand Eczema (CHE) population by its Severity - specific cases
  • Understand the magnitude of Chronic Hand Eczema (CHE) population by its subgroup-specific cases
  • The Chronic Hand Eczema (CHE) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Chronic Hand Eczema (CHE) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

As per the National Eczema Association, Hand Eczema/Hand Dermatitis is a very common condition affecting up to 10% of the population. The same number of estimation is found in the Thyssen et al., (2010) and others. Chronic Hand Eczema is estimated to occur in 5-7% of patients with Hand Eczema. As per Diepgen et al., Severe chronic HE has a major adverse impact on economic and social functions, with although abundant treatment options but with limited efficacy.

The chronic hand eczema registry on long-term patient management (CARPE) registry is the worldwide first registry of CHE that has been initiated in Germany which has a great contribution to health care research of chronic hand eczema. The CARPE was initiated in 2009, with the aim to investigate characteristics and treatment modalities in patients affected by chronic hand eczema in Germany. CARPE Registry-2015 found that mean disease duration was almost 8 years and CHE was graded as very severe or severe in approximately 70% of affected patients. Overall, 41% of patients had an atopic background and a type IV sensitization was reported in 48% of patients. Atopic hand eczema and allergic contact dermatitis were, however, reported in 34% and 22%.

Currently, register on patients with chronic hand eczema data from CARPE and a Swiss "sister-registry" showed that a significant proportion of patients may not receive adequate treatment according to guidelines. Future research will need to make use of longitudinal data to study the course of the disease and the effectiveness of different therapies in a comparative manner

Table of Contents

1. Key Insights

2. Executive summary

3. Chronic Hand Eczema: Patient Overview at a Glance

  • 3.1. Total Patient Share (%) Distribution of Chronic Hand Eczema in 2017
  • 3.2. Total Patient Share (%) Distribution of Chronic Hand Eczema in 2030

4. Epidemiology and Market Methodology

5. Organizations

6. Chronic Hand Eczema: Disease Background and Overview

  • 6.1. Introduction
  • 6.2. Classification
  • 6.3. Etiology
  • 6.4. Symptoms
  • 6.5. Risk Factors
  • 6.6. Pathogenesis
  • 6.7. Defining CHE Severity and Therapeutic Response
  • 6.8. Diagnosis
    • 6.8.1. Differential diagnosis
    • 6.8.2. Guidelines for Diagnosis of hand eczema - European Society of Contact Dermatitis (ESCD)
  • 6.9. Diagnostic Algorithm

7. Epidemiology and Patient Population

  • 7.1. Key Findings

8. Total Prevalent Cases of Chronic Hand Eczema in 7MM

9. United States Epidemiology

  • 9.1. Assumptions and Rationale
    • 9.1.1. Total Prevalent Cases of Chronic Hand Eczema in the United States
    • 9.1.2. Gender-Specific Cases of Chronic Hand Eczema in the United States
    • 9.1.3. Diagnosed Cases of Chronic Hand Eczema in the United States
    • 9.1.4. Severity Specific Cases of CHE in the United States
    • 9.1.5. Subgroup-Specific Cases of CHE in the United States
    • 9.1.6. Age-Specific Cases of CHE in the United States

10. EU5 Epidemiology

  • 10.1. Germany Epidemiology
    • 10.1.1. Assumptions and Rationale
    • 10.1.2. Total Prevalent Cases of Chronic Hand Eczema in Germany
    • 10.1.3. Gender-Specific Cases of Chronic Hand Eczema in Germany
    • 10.1.4. Diagnosed Cases of Chronic Hand Eczema in Germany
    • 10.1.5. Severity Specific Cases of CHE in Germany
    • 10.1.6. Subgroup-Specific Cases of CHE in Germany
    • 10.1.7. Age-Specific Prevalent Cases of CHE in Germany
  • 10.2. France Epidemiology
    • 10.2.1. Assumptions and rationale
    • 10.2.2. Total Prevalent Cases of Chronic Hand Eczema in France
    • 10.2.3. Gender-Specific Cases of Chronic Hand Eczema in France
    • 10.2.4. Diagnosed Cases of Chronic Hand Eczema in France
    • 10.2.5. Severity Specific Cases of CHE in France
    • 10.2.6. Subgroup-Specific Cases of CHE in the United States
    • 10.2.7. Age-Specific Cases of CHE in France
  • 10.3. Italy Epidemiology
    • 10.3.1. Assumptions and Rationale
    • 10.3.2. Total Prevalent Cases of Chronic Hand Eczema in Italy
    • 10.3.3. Gender-Specific Cases of Chronic Hand Eczema in Italy
    • 10.3.4. Diagnosed Cases of Chronic Hand Eczema in Italy
    • 10.3.5. Severity Specific Cases of CHE in Italy
    • 10.3.6. Subgroup-Specific Cases of CHE in Italy
    • 10.3.7. Age-Specific Cases of CHE in Italy
  • 10.4. Spain Epidemiology
    • 10.4.1. Assumptions and Rationale
    • 10.4.2. Total Prevalent Cases of Chronic Hand Eczema in Spain
    • 10.4.3. Gender-Specific Cases of Chronic Hand Eczema in Spain
    • 10.4.4. Diagnosed Cases of Chronic Hand Eczema in Spain
    • 10.4.5. Severity Specific Cases of CHE in Spain
    • 10.4.6. Subgroup-Specific Cases of CHE in Spain
    • 10.4.7. Age-Specific Cases of CHE in Spain
  • 10.5. United Kingdom Epidemiology
    • 10.5.1. Assumptions and Rationale
    • 10.5.2. Total Prevalent Cases of Chronic Hand Eczema in the UK
    • 10.5.3. Gender-Specific Cases of Chronic Hand Eczema in the UK
    • 10.5.4. Diagnosed Cases of Chronic Hand Eczema in the UK
    • 10.5.5. Severity Specific Cases of CHE in the UK
    • 10.5.6. Subgroup-Specific Cases of CHE in the UK
    • 10.5.7. Age-Specific Cases of CHE in the UK

11. Japan Epidemiology

  • 11.1. Assumptions and Rationale
    • 11.1.1. Total Prevalent Cases of Chronic Hand Eczema in Japan
    • 11.1.2. Gender-Specific Cases of Chronic Hand Eczema in Japan
    • 11.1.3. Diagnosed Cases of Chronic Hand Eczema in Japan
    • 11.1.4. Severity Specific Cases of CHE in Japan
    • 11.1.5. Subgroup-Specific Cases of CHE in Japan
    • 11.1.6. Age-Specific Cases of CHE in Japan

12. KOL Views

13. Appendix

14. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight